{
    "Case ID": "004754",
    "Crime_Name": [
        "Patent Infringement Dispute"
    ],
    "Crime_Type": [
        "Property Crimes"
    ],
    "Dispute_Type": [
        "Patent Infringement Dispute"
    ],
    "Legal_Issue": [
        "Whether Novopharm's proposed drug infringes Biovail's patents ('320 and '754) for Wellbutrin® SR"
    ],
    "Governing_Law": [
        "Patented Medicines (Notice of Compliance) Regulations, SOR/93-133"
    ],
    "Procedural_Stage": [
        "Regulatory approval stage; pre-market dispute"
    ],
    "Evidence_Assessment": [
        "Expert testimony on chemical composition similarities between HPMC and HPC; comparison of manufacturing processes"
    ],
    "Decision_Outcome": [
        "Biovail's application dismissed; Novopharm does not infringe either the '320 or '754 patent"
    ],
    "Burden_of_Proof": [
        "On Novopharm to justify allegations in Notice of Allegation"
    ],
    "Credibility_Factor": [
        "Court found expert testimony credible but determined HPMC was essential to '320 claims, excluding HPC as a variant"
    ],
    "Legal_Rule": [
        "Purposive construction of patent claims; determination of essential elements in patented invention"
    ],
    "Standard_of_Review": [
        "Justification of allegations without final determination of validity or infringement"
    ],
    "Procedural_Issue": [
        "Use of NOC proceedings to delay generic market entry"
    ],
    "Grounds_for_Claim": [
        "Allegation that Novopharm’s generic version of Wellbutrin® SR infringes Biovail’s patents"
    ],
    "Outcome_on_Merits": [
        "No infringement found; Biovail failed to establish grounds to block approval"
    ],
    "Decision_Maker": [
        "Federal Court (implied from context)"
    ],
    "Judicial_Review_Outcome": [
        "Application dismissed"
    ],
    "Review_Standard": [
        "Balance of convenience and justification of allegations under NOC Regulations"
    ],
    "Procedural_Fairness_Assessment": [
        "Process followed regulatory framework for patent disputes in drug approval context"
    ],
    "Key_Evidence_Considered": [
        "Expert analysis of HPMC vs. HPC; description of osmotic vs. hydrogel systems in '754 patent"
    ],
    "Legal_Framework": [
        "NOCP Regulations framework for patent-based challenges to generic drug approvals"
    ],
    "Applicant_Challenge": [
        "Biovail sought to prevent regulatory approval of Novopharm’s generic drug"
    ],
    "Court_Result": [
        "Novopharm permitted to proceed with development and regulatory approval process"
    ],
    "Legal_Rule_Source": [
        "SOR/93-133; Canadian patent law principles including purposive claim construction"
    ],
    "Standard_of_Proof": [
        "Justification of allegations on a balance of probabilities"
    ],
    "Defendant_Response": [
        "Novopharm denied infringement via Notice of Allegation, asserting non-infringement of '320 and '754 patents"
    ],
    "Evidence_Type": [
        "Scientific expert testimony, patent claims, technical disclosures"
    ],
    "Remedy_Requested": [
        "Interim injunction to prevent regulatory approval pending patent expiry"
    ],
    "Outcome": [
        "Remedy denied; Novopharm free to proceed"
    ],
    "Decision_Authority": [
        "Federal Court of Canada"
    ],
    "Remedy_Sought": [
        "Prevention of regulatory approval for generic Wellbutrin® SR"
    ],
    "Resolution_Mechanism": [
        "Judicial determination under NOC Regulations"
    ],
    "Legal_Provision": [
        "Patented Medicines (Notice of Compliance) Regulations, SOR/93-133"
    ],
    "Authority": [
        "Federal Court of Canada"
    ],
    "Claimant_Status": [
        "Patent holder (Biovail) seeking to enforce rights against generic applicant"
    ],
    "Legal_Provision_Cited": [
        "SOR/93-133"
    ],
    "Grounds_for_Inadmissibility_or_Allegation": [
        "Non-infringement due to absence of essential elements and different technological process"
    ],
    "Applicable_Process": [
        "Notice of Compliance litigation process under Canadian patent linkage regime"
    ],
    "Outcome_of_Review": [
        "Appeal or review not indicated; decision finalized at trial level"
    ],
    "Pending_Relief_or_Application": [
        "Request to block regulatory approval was pending and ultimately denied"
    ],
    "Jurisdiction": [
        "Canada"
    ],
    "Governing_Rule": [
        "Patented Medicines (Notice of Compliance) Regulations"
    ]
}